Gatell JM - Search Results

1

Dendritic cell based vaccines for HIV infection: the way ahead.

García F, Plana M, Climent N, León A, Gatell JM, Gallart T. García F, et al. Among authors: gatell jm. Hum Vaccin Immunother. 2013 Nov;9(11):2445-52. doi: 10.4161/hv.25876. Epub 2013 Aug 2. Hum Vaccin Immunother. 2013. PMID: 23912672 Free PMC article. Review.

2

Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals.

Climent N, Guerra S, García F, Rovira C, Miralles L, Gómez CE, Piqué N, Gil C, Gatell JM, Esteban M, Gallart T. Climent N, et al. Among authors: gatell jm. PLoS One. 2011;6(5):e19644. doi: 10.1371/journal.pone.0019644. Epub 2011 May 18. PLoS One. 2011. PMID: 21625608 Free PMC article.

3

Loading dendritic cells with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses.

Climent N, Munier S, Piqué N, García F, Pavot V, Primard C, Casanova V, Gatell JM, Verrier B, Gallart T. Climent N, et al. Among authors: gatell jm. Vaccine. 2014 Oct 29;32(47):6266-76. doi: 10.1016/j.vaccine.2014.09.010. Epub 2014 Sep 19. Vaccine. 2014. PMID: 25240755

4

Loading dendritic cells with gold nanoparticles (GNPs) bearing HIV-peptides and mannosides enhance HIV-specific T cell responses.

Climent N, García I, Marradi M, Chiodo F, Miralles L, Maleno MJ, Gatell JM, García F, Penadés S, Plana M. Climent N, et al. Among authors: gatell jm. Nanomedicine. 2018 Feb;14(2):339-351. doi: 10.1016/j.nano.2017.11.009. Epub 2017 Nov 20. Nanomedicine. 2018. PMID: 29157976

5

Effect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon α-2a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial.

Leal L, Couto E, Sánchez-Palomino S, Climent N, Fernández I, Miralles L, Romero Y, González T, Maleno MJ, Paño B, Pich J, Nicolau C, Gatell JM, Plana M, García F; DCV3-RISVAC04 Study Group. Leal L, et al. Among authors: gatell jm. Front Immunol. 2021 Nov 11;12:767370. doi: 10.3389/fimmu.2021.767370. eCollection 2021. Front Immunol. 2021. PMID: 34858423 Free PMC article. Clinical Trial.

6

Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection.

García F, Lejeune M, Climent N, Gil C, Alcamí J, Morente V, Alós L, Ruiz A, Setoain J, Fumero E, Castro P, López A, Cruceta A, Piera C, Florence E, Pereira A, Libois A, González N, Guilá M, Caballero M, Lomeña F, Joseph J, Miró JM, Pumarola T, Plana M, Gatell JM, Gallart T. García F, et al. Among authors: gatell jm. J Infect Dis. 2005 May 15;191(10):1680-5. doi: 10.1086/429340. Epub 2005 Apr 11. J Infect Dis. 2005. PMID: 15838795

7

Adenosine deaminase enhances T-cell response elicited by dendritic cells loaded with inactivated HIV.

Climent N, Martinez-Navio JM, Gil C, Garcia F, Rovira C, Hurtado C, Miralles L, Gatell JM, Gallart T, Mallol J, Lluis C, Franco R. Climent N, et al. Among authors: gatell jm. Immunol Cell Biol. 2009 Nov-Dec;87(8):634-9. doi: 10.1038/icb.2009.53. Epub 2009 Aug 11. Immunol Cell Biol. 2009. PMID: 19668260

8

Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine.

López A, van der Lubbe N, Sánchez-Palomino S, Arnedo M, Nomdedeu M, Castro P, Guilà M, Maleno MJ, García F, Gallart T, Gatell JM, Plana M. López A, et al. Among authors: gatell jm. Vaccine. 2009 Oct 19;27(44):6166-78. doi: 10.1016/j.vaccine.2009.08.021. Epub 2009 Aug 26. Vaccine. 2009. PMID: 19712765

9

Increased alpha-defensins 1-3 production by dendritic cells in HIV-infected individuals is associated with slower disease progression.

Rodríguez-García M, Climent N, Oliva H, Casanova V, Franco R, Leon A, Gatell JM, García F, Gallart T. Rodríguez-García M, et al. Among authors: gatell jm. PLoS One. 2010 Feb 25;5(2):e9436. doi: 10.1371/journal.pone.0009436. PLoS One. 2010. PMID: 20195543 Free PMC article.

10

Assessment of migration of HIV-1-loaded dendritic cells labeled with 111In-oxine used as a therapeutic vaccine in HIV-1-infected patients.

Ruiz A, Nomdedeu M, Ortega M, Lejeune M, Setoain J, Climent N, Fumero E, Plana M, León A, Alós L, Piera C, Lomeña F, Gatell JM, Gallart T, García F. Ruiz A, et al. Among authors: gatell jm. Immunotherapy. 2009 May;1(3):347-54. doi: 10.2217/imt.09.5. Immunotherapy. 2009. PMID: 20635955 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

836 results

Search Page